Media Summary: Respiratory disease surge, Fall 2022, United States; U.S. Influenza activity update; Preliminary 2022-23 influenza vaccine ... Agency Updates; Epidemiology of meningococcal disease in the United States; Pfizer pentavalent meningococcal vaccine; ... Influenza activity update; Recommending enhanced seasonal influenza vaccines in adults age 65 and older--potential impacts on ...
February 2023 Acip Meeting Covid - Detailed Analysis & Overview
Respiratory disease surge, Fall 2022, United States; U.S. Influenza activity update; Preliminary 2022-23 influenza vaccine ... Agency Updates; Epidemiology of meningococcal disease in the United States; Pfizer pentavalent meningococcal vaccine; ... Influenza activity update; Recommending enhanced seasonal influenza vaccines in adults age 65 and older--potential impacts on ... Introduction; Epidemiology of mpox during 2022 outbreak in the United States; JYNNEOS vaccine safety; JYNNEOS vaccine ... Cost effectiveness of the GSK and Pfizer vaccines (main CDC model); Comparison of cost effectiveness results of the main CDC ... Updates to Clinical Considerations; Canadian experience and evidence with
The National Vaccine Advisory Committee (NVAC) recommends ways to achieve optimal prevention of human infectious diseases ... Introductions; Current epidemiology of pneumoccocal disease and pneumococcal vaccine coverage in US adults; PCV20 Phase ... Cost effectiveness analysis for nirsevimab – CDC model; Cost effectiveness analysis for nirsevimab – Comparison to ...
